Ownership
Public
Employees
~100
Therapeutic Areas
HematologyGastroenterology
Stage
Commercial
Modalities
Small molecule

Emmaus Medical General Information

Commercial stage company with FDA-approved Endari (L-glutamine) for sickle cell disease. Showed positive results in Phase 3 trials with reduced acute complications and hospitalizations. Expanding internationally with approvals in multiple Middle East countries.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Endari
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Emmaus Medical's pipeline data

Book a demo

Key Partnerships

taiba Healthcare, Express Scripts, Cardinal Health, McKesson, Kainos Medicine

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Emmaus Medical Funding

Deal TypeDateAmountStatusStage
Later Stage VCJun 30, 2022$110.0KCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Emmaus Medical's complete valuation and funding history, request access »